Olaparib

About

Therapy type: Targeted therapy

Therapy strategy: PARP inhibition

Mappings

NCI Thesaurus: Olaparib (ncit:C71721)

RxNorm: olaparib (rxcui:1597582, omop:45892579)

SNOMED: Olaparib (sctid:432162002, omop:4332351)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
EMA (1) FDA (2) HSE (2)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (2) HSE (2)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	Ovarian Epithelial Tumor	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	High-Grade Serous Fallopian Tube Cancer	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1)	BRCA2 oncogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (1) FDA (1) HSE (1)	HRD	Peritoneal Serous Carcinoma	Bevacizumab, Olaparib
EMA (2) FDA (2) HSE (1)	BRCA1 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
EMA (2) FDA (2) HSE (1)	BRCA2 pathogenic variants, HER2-negative	Invasive Breast Carcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Pancreatic Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
EMA (1) FDA (1) HSE (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	ATM pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	ATM oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BARD1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BARD1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRIP1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRIP1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CDK12 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CDK12 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CHEK1 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CHEK1 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CHEK2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	CHEK2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	FANCL pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	FANCL oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	PALB2 pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	PALB2 oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD51B pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD51C pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD51C oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD51D pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD51D oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD54L pathogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	RAD54L oncogenic variants	Prostate Adenocarcinoma	Olaparib
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisolone
FDA (1)	BRCA1 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA1 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 oncogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
FDA (1)	BRCA2 pathogenic variants	Prostate Adenocarcinoma	Abiraterone acetate, Olaparib, Prednisone
EMA (1)	pMMR	Endometrial Carcinoma	Carboplatin, Durvalumab, Olaparib, Paclitaxel
EMA (1)	pMMR	Endometrial Carcinoma	Durvalumab, Olaparib